º

INVESTORFORUM

October 17-18, 2017 | The Westin St. Francis, San Francisco, CA

Accelerate discovery. Amplify returns.

-1-

The BIO Investor Forum is an international biotech investor conference focused on investment trends and op-portunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2018.

Why Investors AttendHEAR from and meet with executives at the top life sciences growth companies.

EVALUATE fresh investment opportunities including compatible, complementary and competitive companies.

BENEFIT from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.

GET A ‘BIG PICTURE’ OVERVIEW of the industry and the issues affecting product innovation, capitalization, and commercialization.

Why Companies Attend MEET one-on-one with new and current investors, analysts, and partnering companies.

GET THE PULSE on the latest life sciences investment trends from sophisticated investment and company executives.

PRESENT your business case to qualified investors and potential partners.

NETWORK with peers, investors and collaboration partners.

-1-

880+ attendees 2,100+ partnering meetings scheduled

170 private and public company presentations 344 partnering companies

-2--2-

2017 Advisory Committee

Scott C. Brun, MDVice President, Corporate Strategy Office Head, AbbVie Ventures

Mahima Agochiya, PhDBusiness Development & Program Manager, SPARK Translational Research Program, School of Medicine, Stanford University

Julia C. Owens, PhDPresident and Chief Executive Officer, Millendo Therapeutics

Lynn Seely, MDPresident and Chief Executive Officer, Myovant Sciences

Asish K. Xavier, PhDVice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.

Rajeev Dadoo, PhDPartner, S.R. One, Limited

David H. Donabedian, PhDVenture Partner, Longwood Fund

Tao Huang, PhDJ.D. Venture Partner, Internal Legal and IP Counsel, Cenova Capital

Charlotte Hubbert, PhDPartner, Gates Foundation Venture Capital

Patrick EnrightManaging Director, Longitude Capital

Wendye Robbins, MDPresident and Chief Executive Officer, Blade Therapeutics

Jennifer Landress, CMPSenior Vice President and Chief Operating Officer, Biocom

James AntonopoulosManaging Director and Co-Head of Healthcare Investment Banking, ROTH Capital Partners

Sara RadcliffePresident & CEO, California Life Sciences Association (CLSA)

Matthew Roden, PhDVice President and Head of Strategic Corporate Development, Bristol-Myers Squibb

Jan HughesJHBIO Business Development, BioPacific Investors

Tim NoblittConsultant, Corporate Business Development, Eli Lilly and Company

John MillerChief Executive Officer, Tourette Association of America

-3--3-

BIO SPARK Showcase Event

Monday, October 16, 2017Time Spark Affiliate and Program

1:00 PM - 1:10 PMWelcome from SPARK Translational Research Program, Stanford Medicine

• Daria Mochly-Rosen, PhD, Director• Kevin Grimes, MD, Co-Director

1:10 PM - 1:30 PMStanford University- Tranquis Therapeutics Targeting Myeloid Cell Metabolism for the Treatment of Neurodegenerative Disease Ed Engleman

1:30 PM - 1:50 PMNational Taiwan University Development of Potential Therapeutic Agents for Irritable Bowel Syndrome Ling-Wei Hsin

1:50 PM - 2:10 PMKyoto University Antivirus drug FIT-039 Dr. Masahiko Ajiro

2:10 PM - 2:30 PMStanford University Novel SM for Alzheimer’s Disease Mehrdad Shamloo

2:30 PM - 2:40 PM Break

2:40 PM - 3:00 PMTMU SPARK Development of Antibody Drug AP001 Against a Novel Tumor Marker Protein AP for Human Cancer Treatment Yu-Ching Le

3:00 PM - 3:20 PMKyoto University Pain killer without adverse effects Dr. Masatoshi Hagiwara

3:20 PM - 3:40 PMStanford University Point-of-care diagnostic to measure hyperammonemia in blood Matthew W. Kanan

3:40 PM - 4:00 PMSPARK Indiana- Theratome, Inc Injectable Biologic for Brain Ischemia Michael Coleman

4:00 PM - 4:10 PM Break

4:10 PM - 4:30 PMKyoto University Neurogenesis inducer ALGERNON Dr. Akiko Kobayashi

4:30 PM - 4:50 PMStanford University- Hyalos Therapeutics Stopping Autoimmune Disease by Oral Induction of Treg Marc Unger

4:50 PM - 5:10 PMKyoto University Apoptosis inducer of cancer cells Dr. Masayasu Toyomoto

5:10 PM - 5:30 PMNational Taiwan University Novel NMDA Modulator: RS-D7 Y. Jane Tseng

5:30 PM - 6:30 PM Reception

This pre-#BIF17 Showcase is free to attend but RSVP is required at https://www.bio.org/events/bio-investor-forum/spark-showcase

The BIO SPARK Showcase Event provides an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding. The symposium will feature a dozen presentations from a mix of international, translational research start-ups.

AT STANFORD

SPARK

-4--4-

#BIF17 Programming Schedule

Plenary Luncheon Fireside ChatsKristina Burow, Managing Director, San Francisco, ARCH Venture PartnersTuesday, October 17, 2017 12:00 pm - 1:25 pmModerator: Effie Toshav, Partner, Fenwick & West LLP

Richard Scheller, PhD, Chief Science Officer & Head of Therapeutics, 23andMeWednesday, October 18, 201712:00 pm - 1:25 pm

PanelsBispecific Antibodies to Supercharge Oncology TreatmentsTuesday, October 17, 8:30-9:25 am

Antibody-based therapy for cancer is one of the most successful strategies for treating patients.  With the introduction of bispecific antibodies, we are now able to combine the targeting specificity of monoclonal antibodies with the cytotoxic effects of cellular therapy.  While industry reports estimate that by 2023, the bispecific antibodies market is estimated to be worth USD 4.4 billion, we can anticipate this estimate to increase multiple-folds due to the significant advances and positive results being enabled by immuno-oncology therapy.  This session will highlight the innovative pipelines and combo therapies utilizing a bispecific approach.

Moderator: TBDPanelists:

• Edgardo Baracchini, PhD, Chief Business Officer, Xencor

• William J. Newell, Chief Executive Officer, Sutro Biopharma

• Ali Tehrani, PhD, President and Chief Executive Officer, Zymeworks

“ Good opportunity to meet with investors and Pharma representatives and establish relationships that may eventually lead to a partnership.”

-5--5-

#BIF17 Programming Schedule

Prioritizing Translational Research BottlenecksTuesday, October 17, 9:30-10:40 am

Recent research has suggested a 29-year gap between a biopharma technology’s discovery and it becoming an established treatment. This research also fails to find a correlation between rising numbers of published biomedical research papers and the stable rate of approval of new medicines. Given the preciousness of patent lifetimes, even small percentage improvements in the translational research process could yield significant economic benefits, as well as helping more patients sooner. This session will discuss the major bottlenecks in the commercialization of medically promising basic research and propose new approaches to addressing those challenges.

Moderator: Simone Fishburn, PhD, Editor, BioCentury InnovationsPanelists:

• Chris Garabedian, Chairman and CEO, Xontogeny• Kevin Grimes, MD, Co-Director, SPARK Translational Research Program, Stanford University• Kate Holt, PhD, Director, Business & Technology Development, North Carolina Biotechnology Center• Stephanie Marrus, Director, Entrepreneurship Center, University of California, San Francisco (UCSF)• Laura McNamee, PhD, Center for Integration of Science and Industry, Bentley University

Addressing Antimicrobial Resistance: New Research and Funding OpportunitiesTuesday, October 17, 10:45-11:40 am

The CDC estimates that at least 700,000 people die each year from drug-resistant infections.  Due to the rising need to develop new antibiotics, a number of new promising targets have been identified in recent years and multiple new funding opportunities have also surfaced to provide support.  For example, the CDC, BARDA, the Wellcome Trust, and many others are all committing resources through new initiatives, like the CARB-X grants, to help advance novel, life-saving antibiotics.  This session will highlight innovative developments in researching new drugs as well as discuss strategies and funding models responding to the challenge of antimicrobial resistance.

Moderator: Gregory Frank, PhD, Director, Infectious Disease Policy, Biotechnology Innovation OrganizationPanelists:

• Shelley Chu, MD, PhD, Partner, Abingworth• Ciara Kennedy, PhD, President and CEO, Amplyx

Pharmaceuticals, Inc. • David Puerta, PhD, Chief Operating Officer and Vice

President of Discovery, Forge Therapeutics • Ted Schroeder, President and CEO, Zavante Therapeutics

(Speakers added daily. Please visit www.bio.org/investorforum for most up to date program and confirmed presenters).

-6--6-

#BIF17 Programming Schedule

Acceleration in Cross-Pacific Investment Activities and Opportunities: Widening the NetworkTuesday, October 17, 2:00-2:55 pm

Foreign direct investment in U.S. biopharma has more than doubled in the past three years, with more than USD 4.5B dollars committed in 2016 and 2017 tracking ahead of last year, the role of cross-Pacific biotech investments is accelerating. The eagerness of China-based and other investors from the region to support foreign biotechnology development as well as the maturation of Asian start-ups into having assets ready for licensing adds new dimensions to conventional business development partnership processes. This session will examine some of the largest recent deals with experts from the Asia venture communities seeking to globalize the lessons of Silicon Valley. You will also hear from biopharmas collaborating on a cross-Pacific basis who can share tips for CEOs on making relevant connections to expand your pool of potential, interested partners.  

Moderator: TBDPanelists:

• Tao Huang, PhD, JD, Venture Partner, Internal Legal and IP Counsel, Cenova Capital• David Lucchino, Co-founder, President and Chief Executive Officer, Frequency Therapeutics• Sofie Qiao, PhD, President and CEO, Vivace Therapeutics• Greg Scott, Founder and Chairman, ChinaBio Group• BT Slingsby, MD, PhD, MPH, CEO and Executive Director, Global Health Innovative Technology (GHIT) Fund

View from the Board—Navigating New Funding Rounds with Current VC DirectorsTuesday, October 17, 3:15-4:10 pm

When raising a seed round of venture capital, the focus of founders tends toward securing meetings and “acing” their pitches. It is a critical moment in the growth of an early-stage biotech that the first interested party is secured in order to more easily convince other investors to join and complete that round of funding. But what happens when you do succeed in generating interest and commitments for your initial round, and the focus shifts to fundraising new funding rounds? CEOs must then walk the fine line during discussions with the current board regarding new investor capital contributions, dilution rights, criteria for new board members, and the overall, long-term health of the company. The panel of start-up executives, directors, and investors will discuss their perspectives on how to crystalize and close subsequent-stage investment rounds, a complex and unclear path from the outside, but a vital step in the process for founders, while navigating the many personalities and interests involved.

Moderator: Michael J. O’Donnell, Partner, Morrison & Foerster LLPPanelists:

• Rajeev Dadoo, PhD, Partner, SR One• David H. Donabedian, PhD, Chief Executive Officer, Axial Biotherapeutics; Partner, Longwood Fund• Julie Papanek Grant, Partner, Canaan Partners• Julia C. Owens, PhD, President & CEO, Millendo Therapeutics, Inc.• Camille Samuels, Partner, Venrock

-7--7-

#BIF17 Programming Schedule

Practical Approaches for Improving Leadership DiversityTuesday, October 17, 4:15-5:10 pm

Despite a workforce with more women graduating college than men, data from Liftstream’s 2017 analysis of biopharma boards finds women constitute fewer than 11% of directors—and that number is largely unchanged since 2012, despite robust expansion in the industry. Similar analysis finds the same pattern for women partners at venture capital firms and for the degrees of diversification of other influential positions in categories other than gender. Traditional decision-maker recruitment processes often fail to reflect the employee bases they lead or patient populations they serve. This session will focus on practical approaches and successful examples to diversify leadership recruitment efforts, create inclusive cultures for development/retention, and better align organizations with the full measure of talented people available.

Moderator: Helen Torley, M.B. Ch. B., M.R.C.P., President and CEO, HalozymePanelists:

• Sabrina Martucci Johnson, Chief Executive Officer and Founder, Daré Bioscience, Inc.• Nina Kjellson, Partner, Canaan Partners• Ted W. Love, MD, Chief Executive Officer, Global Blood Therapeutics• Robin Toft, President & CEO, Toft Group Executive Search

Preparing for the Value Discussion with Investors, Payers, and Patients as Part of the Social ContractWednesday, October 18, 8:30-9:25 am

The public debate regarding appropriate levels of spending on prescription medicines has continued to grow and take root since the early headlines during the last U.S. presidential election. BioCentury’s recent “Back to School” essay argues the notion of a social contract deserves re-examination at a time of widespread public concern over the motivations of biopharma companies and the value they generate for patients. Major payers, pharmacy benefit managers, and value framework advocates have increased the pressure to have clearly defined arguments available earlier than ever about a proposed therapy’s value to patients and economic impact on healthcare systems, in addition to its clinical benefit. As investors readjust their approach to including pricing models in their risk calculations, CEOs need to be aware of the expanding range of new therapy payment models under development and effective ways of communicating the value of innovative medicines, even when early in development. This session will hear from multiple sides of the current discussion about which approaches are proving most constructive.

Moderator: Susan Schaeffer, Editor, BioCenturyPanelists:

• Paul Biondi, Senior Vice President, Head of Business Development, Bristol-Myers Squibb• Peter Lomedico, PhD, Director, Industry Partnerships & Investments, JDRF T1D Fund• Wendye Robbins, MD, President and Chief Executive Officer, Blade Therapeutics

“ BIO One-on-One Partnering is the best mechanism for meeting potential investors and collaborators.”

-8--8-

#BIF17 Programming Schedule

Policy Outlook—Planning Under FDARA and the Trump Administration’s Healthcare PlansWednesday, October 18, 9:45-10:40 am

With the adjustment of prescription drug user fees and new review process commitments, the enactment of FDARA legislation updates the regulatory landscape for drug developers. This panel of people close to the policymaking process will share the latest data on FDA expectations, plus discuss the Trump Administration’s stances on healthcare spending, the opioid addiction crisis, and tax policies that will affect biopharmas both immediately and in the years ahead.

Moderator: Cartier Esham, PhD, Executive Vice President for Emerging Companies, Biotechnology Innovation OrganizationPanelists:

• Shawn Iadonato, PhD, Chief Executive Officer, Kineta, Inc. • Brian Rye, Analyst, Bloomberg Intelligence• Diana Shineman, PhD, Vice President of Research and Medical Programs, Tourette Association of America

Liquid Biopsies: Possibilities and ChallengesWednesday, October 18, 10:45-11:40 am

As FDA approvals of diagnostic tests to detect progress of identified tumors via genetic fragments in blood samples progress into medical practice, the flow of investments into broadening the validation and reach of liquid biopsies is accelerating, with more than USD 1 billion announced for startups in this space in the past year. This session will feature companies trying to expand this frontier, the investors distinguishing among the competing technologies, the therapeutic partners who might benefit from such tests, and clinical experts on the most likely pathways innovations will take to reach patients.

Moderator: TBDPanelist:

• Riley Ennis, Chief Operating Officer, Freenome

• Alex Szidon, PhD, Head, West Coast Innovation Hub and Associate Vice President of Business Development & Licensing, Merck

-9--9-

#BIF17 Programming Schedule

Alternative Funding Models: Royalty, Debt, Non-Profit Foundation, Crowdfunding Decision GuidesWednesday, October 18, 1:45-2:55 pm

After a reined in 2016, that saw U.S. biopharmas slow their blistering pace of funding with record-setting quarters from the previous year, which were invested from the coffers of venture capitalists, hedge funds, and public market “crossover” investors, the investment environment has pushed the needle toward more non-traditional parts of the financial swimming pool. This shift has led in part to a resurgent 2017, where investments could easily surpass the USD 8.1B mark from last year. A panel of investment experts will share their views on some of the more innovative ways, than the typical glitz and glam usually associated with taking a company public via a traditional IPO, that companies can use their resources to raise capital and get their start-up actually started up.

Moderator: James Antonopoulos, Managing Director and Co-Head of Healthcare Investment Banking, ROTH Capital PartnersPanelists:

• Patrick Enright, Managing Director, Longitude Capital• Charlotte Hubbert, PhD, Partner, Gates Foundation Venture Capital• Sara Klymkowsky, Senior Associate, Research & Investments at Royalty Pharma Management, LLC• Neil Littman, Director, Business Development, California Institute for Regenerative Medicine (CIRM)• BT Slingsby, MD, PhD, MPH, CEO and Executive Director, Global Health Innovative Technology (GHIT) Fund• James M. Tai, Head of Life Sciences, Senior Vice President, Comerica

Lessons from the Immuno-Oncology Inhibitor Landscape for Neurology and BeyondWednesday, October 18, 3:00-3:55 pm

As long-studied neurological diseases such as Parkinson’s and Alzheimer’s continue to yield disappointing clinical trials success rates, signs are growing that many diseases in CNS and other areas might learn from the positive lessons of immuno-oncology checkpoint inhibitors to enlist the body’s own immunological responses to adjust inflammation and to modify disease progression. This session will feature scientists, entrepreneurs, and investors operating at the frontier of this approach to pursuing new treatment avenues in hopes of helping patients.

Moderator: TBDPanelists:

• Scott C. Brun, MD, Vice President, Corporate Strategy Office Head, AbbVie Ventures• Isaac Ciechanover, MD, President and CEO, Atara Biotherapeutics• Leslie Williams, RN, Director, Founder, President and Chief Executive Officer, ImmunsanT

-10--10-

#BIF17 Programming Schedule

Market Outlook—Evaluating IPO Reliability, M&A Patterns, and the Private Funding ClimateWednesday, October 18, 4:00-4:55 pm

With renewed interest and appealing financial markets, the biopharma sector has had 25 companies complete their IPOs on U.S., European, and Australasia exchanges in the first half of 2017, double the prior year’s pace but less than 2015’s. Will public market exits strengthen or will the M&A climate escape its current slowdown? With cash reserves at large pharma and newly raised private equity funds above historical average levels, the prospects for biotechs in development are bright, but complicated to predict. Hear from active dealmakers which recent deals are resetting market trends in their opinion as they prioritize possible avenues for entrepreneurs seeking the next level of funding. 

Moderator: TBD Panelists:

• Asthika Goonewardene, Senior Biotechnology Analyst, Bloomberg Intelligence• Matthew Roden, PhD, Vice President and Head of Strategic Corporate Development, Bristol-Myers Squibb• Tracy Saxton, PhD, Managing Partner, Pivotal Ventures • Asish K. Xavier, PhD, Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.

(As of 9/11/2017.  Program sessions are subject to change.)

If you have questions or feedback on the program, please email bfallon@bio.org.

“ Great mix of different investors and well executed format.”

“ Panel sessions are interesting and informative.”

-11--11-

Participating Investors

11.2 Capital5AM Ventures6 Dimensions CapitalAbbVie AbingworthAgent CapitalAisling CapitalAltitude Life Science VenturesAphelion CapitalAquiloARCH Venture PartnersArix BioscienceAsahi Kasei AmericaAspire Capital PartnersAstellas Innovation ManagementAstellas Venture ManagementATEL VenturesATEM CapitalBailardBDC CapitalBGI VentureBioMed VenturesBioPacific InvestorsBios PartnersBioSense GlobalBiotech Alliances InternationalBOHE Angel Fund Brace Pharma CapitalBrandon Capital PartnersBridge BankBridgeBio PharmaCanaan PartnersCapital Family OfficeCapital IPChardan Capital MarketsComplete Genomics, BGICrosswave ManagementCSC LeasingDeerfield ManagementDefta PartnersDorset Capital Droia NVEcoR1 CapitalEndurant Capital

Fineman FinancialFirst Light Asset ManagementFrameshiftFTLFundRxGolden SeedsGood Health CapitalGreenSky CapitalH.I.G. BioHealth PartnersHayfin Captial ManagementHealthCare Royalty PartnersHemi VenturesHuret, Rothenberg and Co.Illumina VenturesINKEF CapitalInnovivaIPF PartnersJAFCOJohnson & Johnson - JJDCJuvenile Diabetes Research Foundation

(JDRF)Life Science AngelsLincoln Park CapitalLogue, PCLongitude CapitalLYFE CapitalMarathon Asset ManagementMBL Venture Capital Co.MEDIVATE PARTNERSMerckMerieux DeveloppementMilitia Hill VenturesMission Bay CapitalMitsui Global InvestmentMoore Venture PartnersMPM CapitalNanoDimensionNasdaqNEANew Leaf Venture PartnersNewYorkBIOOceanIQ CapitalOmniCyteOresund Capital

Oxford FinancePivotal - NFLSPoC CapitalPortola Capital PartnersPrevail PartnersProMéxicoProteus Venture PartnersQiming U.S. Healthcare FundRemiges VenturesRoche Venture FundRosetta Capital Santen Pharmaceutical Co.SDL VENTURESShuster CapitalSilicon Valley BankSK TelecomSofinnova VenturesSolar Capital Surveyor CapitalTaiho VenturesTemasekThiel CapitalTMX - TSX & TSXVTosoh USATwo Sigma VenturesU.S. AngelsvenBio PartnersVersant VenturesVivo CapitalW Global Capital/International Capital

Management Wellington FinancialWRF Capital

Below is the preliminary list of participating investors for the 2017 BIO Investor Forum.

-12--12-

Presenting Companies

The following is the list of presenting companies for the 16th Annual BIO Investor Forum. Presenters will consist of Discovery Companies (under $25M raised to date in Seed or Series A financing rounds), established private companies (over $25M raised and in Series B and above) and emerging public companies. A special track of NIH SBIR grant recipients will be presenting also.

Download a spreadsheet of data from the presenting companies for sorting, editing, and notes at https://bit.ly/BIF17DataCARDIOVASCULAR

Adrenomed AGCardio TherapeuticsEidos Therapeutics, Inc.RECARDIO Inc.Resverlogix CorpTARA Biosystems, Inc.TMS Co., Ltd.

CNS/NEUROLOGICALAmygdala Neurosciences, Inc.Aptinyx Inc.biOasis Technologies Inc.Cingulate Therapeutics, LLCCircumvent Pharmaceuticals IncEmbera NeuroTherapeutics, Inc.Epitel, Inc.NeuCyte, Inc.Neuroelectrics Inc.NeurOp Inc.Neuroparticle CorporationProbiodrug AGSpiral Therapeutics IncZosano Pharma

DERMATOLOGYDermala Inc.Edesa BiotechExicure, Inc.Noveome Biotherapeutics, Inc.

DIAGNOSTICSAzooka Life SciencesCellMax LifeDeePath Medical DiagnosticsValtari Bio

DRUG DELIVERYXeris Pharmaceuticals, Inc.

GASTROINTESTINALHepaTx CorporationOrphoMed, Inc.

GENE/CELL THERAPYMangoGen Pharma Inc.Sigilon Therapeutics Inc

IMMUNOLOGYAdvaxis Inc.Bristol-Myers SquibbImmusanT, Inc.

Oncolytics Biotech Inc.OncoSec Medical IncorporatedOrion BioScience Inc

INFECTIOUS DISEASES3i Diagnostics, Inc.Aequor, Inc.AmpliPhi BiosciencesAntiva Biosciences, Inc.Genecure LLCGeneral ProbioticsLexaGene Holdings Inc.Synthetic Biologics, Inc.Vical Incorporated

INFLAMMATIONKadmon Holdings, Inc.Relburn-Metabolomics, Inc.Zyngenia, Inc

MEDICAL DEVICESAethlon Medical, Inc.CytoSorbents CorporationNeuroEM Therapeutics, Inc.Next ScienceSense Diagnostics, LLC

METABOLIC DISEASESOrexigen Therapeutics, Inc.

MULTIPLE THERAPEUTICSLyndra IncMount Tam Biotechnologies, Inc.Silence TherapeuticsSymic Bio, Inc.Vium Inc.

ONCOLOGYAadi Bioscience IncAbilita Bio, Inc.Advaxis, InclAPG TherapeuticsAviara Pharmaceuticals, Inc.BeyondSpring Pharmaceuticals, BioEclipse Therapeutics (Formerly

ConcentRx)Cellanyx DiagnosticsCENTROSECHIME Biotherapeutics, Inc.Circle Pharma, Inc.Context TherapeuticsCue Biopharma, Inc.

DevaCell, Inc.Diffusion Pharmaceuticals Inc.DotBio Pte. Ltd.Eureka TherapeuticsHeat BiologicsHeidelberg Pharma AGHuMurine TechnologiesImmune-Onc Therapeutics, Inc.Immunovaccine Inc.Infinity Pharmaceuticals, Inc.INmune BioInvenra Inc.IRX Therapeutics, Inc.Lin BioScienceMetaStat, Inc.Molecular TemplatesNanOlogy, LLCNanoValent Pharmaceuticals IncNERx BiosciencesNorthern BiologicsNuvOx PharmaOncoceutics, Inc.OncoCyte CorporationOnconova Therapeutics, Inc.Opsona Therapeutics LimitedOrpheus Therapeutics, Inc.RadioMedix IncRafael PharmaceuticalsSierra Oncology, IncSutro Biopharma Inc.Synergys Biotherapeutics, Inc.Tactiva TherapeuticsTargaGenix, IncTizona Therapeutics, Inc.Vidac PharmaViracta Therapeutics, Inc.Zenith Epigenetics

OPHTHALMOLOGYGraybug Vision, Inc.iVeena Delivery Systems inc.

ORPHAN/RARE DISEASESCapricor Therapeutics, Inc.Catalyst Pharmaceuticals, Inc.ChromaDex CorporationEmerald Health PharmaceuticalsImmusoft CorporationPalladio Biosciences, Inc.

OTHERIllumina AcceleratorMedikine, Inc.Origin IncPfenex Inc

PAIN MANAGEMENTTetra Biopharma Inc.

PLATFORM FOR THERAPEUTICS

Berkeley Lights, Inc.Feldan TherapeuticsRXi Pharmaceuticals CorporationSirenas, LLCSirnaomics, Inc

REGENERATIVE MEDICINEFrequency Therapeutics, Inc.ORIG3N, Inc.

REPRODUCTIVE/SEXUAL HEALTH

Episona, Inc.

TOOLS/DRUG DEVELOPMENT SUPPORT TECHNOLOGY

FenoLogica Biosciences, Inc.Molecular Assemblies, Inc.NUProtein Co., Ltd

VACCINESAdjuvance TechnologiesVaxess TechnologiesVerndari Inc.VLP Therapeutics

-13--13-

Registration

BIO offers a number of ways for conference attendees to save money on their registration fees. Discounted rates apply to the following:

Biotech companies that have raised less than $25 million in capital.

Presenting companies bringing three or more attendees.

Companies bringing more than two employees.

Corporations or other entities that use biotechnology or related technologies for research and development of products or information.

Academic institutions.

Qualified institutional and venture investors are eligible for complimentary registration.

Hotel/Venue InformationWestin St. Francis Hotel335 Powell StreetSan Francisco, California 94102Book your room today to also receive the discounted room rate. Reservation requests are based on availability, space is limited.

Register today at bio.org/investorforum

3

3

3

3

3

2017 SponsorsSupporting Bank SponsorsRegional Co-Hosts

Industry Supporter

BIO Double Helix Sponsors BIO Helix Sponsors

Conference Sponsors

Contact us today for a tailored sponsorship package that will meet your business objectives. Please contact:Liz Colangelo at lcolangelo@bio.org or (202) 962-6656.For more information on BIO sponsorships, please contact sponsor@bio.org.

Join the conversation:Learn more about Biotechnology at bio.orgEngage with the Biotech Community at BIOtech-NOW.orgFollow us on Twitter @bio1x1 and tweet with #BIF17Become a fan on Facebook (facebook.com/IAmBiotech)